- Home
- GPUS vs NERV Comparison
GPUS vs NERV Comparison
Compare GPUS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPUS
- NERV
- Stock Information
- Founded
- GPUS 1969
- NERV 2007
- Country
- GPUS United States
- NERV United States
- Employees
- GPUS 424
- NERV N/A
- Industry
- GPUS
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- GPUS
- NERV Health Care
- Exchange
- GPUS NYSE
- NERV Nasdaq
- Market Cap
- GPUS 4.8M
- NERV 12.6M
- IPO Year
- GPUS 1996
- NERV 2014
- Fundamental
- Price
- GPUS $1.35
- NERV $1.77
- Analyst Decision
- GPUS
- NERV Hold
- Analyst Count
- GPUS 0
- NERV 1
- Target Price
- GPUS N/A
- NERV $5.00
- AVG Volume (30 Days)
- GPUS 2.7M
- NERV 12.2K
- Earning Date
- GPUS 08-15-2025
- NERV 08-05-2025
- Dividend Yield
- GPUS N/A
- NERV N/A
- EPS Growth
- GPUS N/A
- NERV N/A
- EPS
- GPUS N/A
- NERV 0.83
- Revenue
- GPUS $93,318,000.00
- NERV N/A
- Revenue This Year
- GPUS N/A
- NERV N/A
- Revenue Next Year
- GPUS N/A
- NERV N/A
- P/E Ratio
- GPUS N/A
- NERV $2.18
- Revenue Growth
- GPUS N/A
- NERV N/A
- 52 Week Low
- GPUS $1.23
- NERV $1.15
- 52 Week High
- GPUS $11.73
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- GPUS N/A
- NERV 57.10
- Support Level
- GPUS N/A
- NERV $1.62
- Resistance Level
- GPUS N/A
- NERV $1.83
- Average True Range (ATR)
- GPUS 0.00
- NERV 0.09
- MACD
- GPUS 0.00
- NERV -0.00
- Stochastic Oscillator
- GPUS 0.00
- NERV 64.29
About GPUS HYPERSCALE DATA INC
Hyperscale Data Inc, formerly Ault Alliance Inc is a diversified holding company. It operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including oil exploration, crane services, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles. The company has six reportable segments: Energy and Infrastructure; Technology and Finance; Sentinum, Inc.; GIGA; TurnOnGreen; ROI; and Ault Global Real Estate Equities, Inc.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.